Angiotensin II, a neuropeptide at the frontier between endocrinology and neuroscience: Is there a link between the angiotensin II type 2 receptor and Alzheimer's disease?

Frontiers in Endocrinology

Volumn 2, Issue AUG, 2010, Pages

  Gallo Payet, Nicole ^a   Guimond, Marie Odile ^a   Bilodeau, Lyne ^a   Wallinder, Charlotta ^b   Alterman, Mathias ^b   Hallberg, Anders ^b  

^a Centre Hospitalier Universitaire de Sherbrooke   (Canada)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Angiotensin II; Angiotensin type 2 receptor; Brain damage; Cognition; Neuron; Vasodilation

Indexed keywords

EID: 84874146940     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00017     Document Type: Review

References (134)

1. Abassi, Z., Winaver, J., and Feuerstein, G. Z. (2009). The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem. Pharmacol. 78, 933-940.
2. Abdalla, S., Lother, H., El Missiry, A., Langer, A., Sergeev, P., El Faramawy, Y., and Quitterer, U. (2009). Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer's disease. J. Biol. Chem. 284, 6554-6565.
3. Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K. L., Barde, Y. A., Duff, K., and Davies, P. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590.
4. Arganaraz, G. A., Konno, A. C., Perosa, S. R., Santiago, J. F., Boim, M. A., Vidotti, D. B., Varella, P. P., Costa, L. G., Canzianm, M., Porcionatto, E. M., Yacubian, A. C., Sakamoto, H., Carrete, H. Jr., Centeno, R. S., Amado, D., Cavalheiro, J. A. Jr., and Mazzacoratti Mda, G. (2008). The renin-angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia 49, 1348-1357.
5. Biessels, G. J., and Kappelle, L. J. (2005). Increased risk of Alzheimer's disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem. Soc. Trans. 33, 1041-1044.
6. Boissonneault,V., Filali, M., Lessard, M., Relton, J., Wong, G., and Rivest, S. (2009). Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 132, 1078-1092.
7. Bosnyak, S., Welungoda, I. K., Hallberg, A., Alterman, R. E., Widdop, M., and Jones, E. S. (2010). Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br. J. Pharmacol. 159, 709-716.
8. Bottari, S. P., Obermuller, N., Bogdal,Y., Zahs, K. R., and Deschepper, C. F. (1992). Characterization and distribution of angiotensin II binding sites in fetal and neonatal astrocytes from different rat brain regions. Brain Res. 585, 372-376.
9. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte,A., and Hof, P. R. (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130.
10. Buisson, B., Laflamme, L., Bottari, S. P., De Gasparo, M., Gallo-Payet, N., and Payet, M.-D. (1995). A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG 108-15 cells. J. Biol. Chem. 270, 1670-1674.
11. Côté, F., Do, T., Laflamme, L., Gallo, J., and Gallo-Payet, N. (1999). Activation of the AT2 receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J. Biol. Chem. 274, 31686-31692.
12. Craft, S. (2006). Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis. Assoc. Disord. 20, 298-301.
13. Craft, S. (2009). The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 66, 300-305.
14. Cui, T., Nakagami, H., Iwai, M., Takeda, Y., Shiuchi, T., Daviet, L., Nahmias, C., and Horiuchi, M. (2001). Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc. Res. 49, 863-871.
15. de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., and Unger, T. (2000). International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472.
16. de Kloet, A. D., Krause, E. G., and Woods, S. C. (2010). The renin angiotensin system and the metabolic syndrome. Physiol. Behav. 100, 525-534.
17. de la Monte, S. M. (2009). Insulin resistance and Alzheimer's disease. BMB Rep. 42, 475-481.
18. de la Torre, J. C. (2004). Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3, 184-190.
19. Dubey, R. K., Flammer, J., and Luscher, T. F. (1998). Angiotensin II and insulin induce growth of ciliary artery smooth muscle: effects of AT1/AT2 antagonists. Invest. Ophthalmol. Vis. Sci. 39, 2067-2075.
20. Fabiani, M. E., Sourial, M., Thomas, W. G., Johnston, C. I., and Frauman, A. G. (2001). Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: implications for the pathophysiology of benign prostatic hyperplasia. J. Endocrinol. 171, 97-108.
21. Farkas, E., and Luiten, P. G. (2001). Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64, 575-611.
22. Feng, Y. H., Sun, Y., and Douglas, J. G. (2002). Gbeta gamma-independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2mediated ITIM-independent activation of SHP-1. Proc. Natl. Acad. Sci. U.S.A. 99, 12049-12054.
23. Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P. R., Rimmer, E., and Scazufca, M. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
24. Fujita, T., Mogi, M., Min, L. J., Iwanami, J., Tsukuda, K., Sakata, A., Okayama, H., Iwai, M., Nahmias, C., Higaki, J., and Horiuchi, M. (2009). Attenuation of cuff-induced neointimal formation by overexpression of angiotensin II type 2 receptorinteracting protein 1. Hypertension 53, 688-693.
25. Funke-Kaiser, H., Reinemund, J., Steckelings, U. M., and Unger, T. (2010). Adapter proteins and promoter regulation of the angiotensin II type 2 receptor - implications for cardiac pathophysiology. J. Renin Angiotensin Aldosterone Syst. 11, 7-17.
26. Gallinat, S., Yu, M., Dorst, A., Unger, T., and Herdegen, T. (1998). Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res. Mol. Brain Res. 57, 111-122.
27. Gallo, J. M., Noble, W., and Rodriguez Martin, T. R. (2007). RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. Cell.Mol.LifeSci. 64, 1701-1714.
28. Gao, L., Wang, W., Li, H., Sumners, C., and Zucker, I. H. (2008). Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure and urine excretion in normal rats. Hypertension 51, 521-527.
29. Gelosa, P., Pignieri, A., Fändriks, L., de Gasparo, M., Hallberg, A., Banfi, C., Castiglioni, L., Turolo, L., Guerrini, U., Tremoli, E., and Sironi, L. (2009). Stimulation of AT2 receptor exerts beneficial effects in strokeprone rats: focus on renal damage. J. Hypertens. 27, 2444-2451.
30. Gendron, L., Oligny, J. F., Payet, M. D., and Gallo-Payet, N. (2003a). Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J. Biol. Chem. 278, 3606-3614.
31. Gendron, L., Payet, M., and Gallo-Payet, N. (2003b). The AT2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J. Mol. Endocrinol. 31, 359-372.
32. Georgsson, J., Rosenstrom, U., Wallinder, C., Beaudry, H., Plouffe, B., Lindeberg, G., Botros, M., Nyberg, F., Karlen, A., Gallo-Payet, N., and Hallberg, A. (2006). Short pseudopeptides containing turn scaffolds with high AT2 receptor affinity. Bioorg. Med. Chem. 14, 5963-5972.
33. Georgsson, J., Skold, C., Botros, M., Lindeberg, G., Nyberg, F., Karlen, A., Hallberg, A., and Larhed, M. (2007). Synthesis of a new class of druglike angiotensin II Cterminal mimics with affinity for the AT2 receptor. J. Med. Chem. 50, 1711-1715.
34. Georgsson, J., Skold, C., Plouffe, B., Lindeberg, G., Botros, M., Larhed, M., Nyberg, F., Gallo-Payet, N., Gogoll, A., Karlen, A., and Hallberg, A. (2005). Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity. J. Med. Chem. 48, 6620-6631.
35. Grammatopoulos, T. N., Jones, S. M., Ahmadi, F. A., Hoover, B. R., Snell, L. D.,Skoch,J.,Jhaveri,V.V.,Poczobutt, A. M., Weyhenmeyer, J. A., and Zawada, W. M. (2007). Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2, 1-17.
36. Grammatopoulos, T. N., Morris, K., Bachar, C., Moore, S., Andres, R., and Weyhenmeyer, J. A. (2004). Angiotensin II attenuates chemical hypoxia-induced caspase-3 activation in primary cortical neuronal cultures. Brain Res. Bull. 62, 297- 303.
37. Guimond, M. O., Roberge, C., and Gallo-Payet, N. (2010a). Fyn is involved in angiotensin II type 2 receptor-induced neurite outgrowth, but not in p42/p44mapk in NG108-15 cells. Mol. Cell. Neurosci. 45, 201-212.
38. Guimond, M. O., Wallinder, C., Alterman, M., Hallberg, A., and Gallo-Payet, N. (2010b). "The selective nonpeptide drug-like ligand (M24, formerly C21) as a tool to investigate the potential link between activation of the angiotensin II type-2 receptor (AT2R) and cognitive impairment," in The 7th International Congress of Neuroendocrinology, Rouen. Available at: http://icn2010.univrouen.fr/page.php?page=program_ scientific: O-20
39. Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
40. Hanger, D. P., Anderton, B. H., and Noble, W. (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119.
41. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
42. Hein, L., Barsh, G., Pratt, R., Dzau, V., and Kobilka, B. (1995). Behavioural and cardiovascular effects of disrupting the angiotensin II type2receptorinmice.Nature 377, 744-747.
43. Hernandez, F., and Avila, J. (2008). The role of glycogen synthase kinase 3 in the early stages of Alzheimer's disease. FEBS Lett. 582, 3848-3854.
44. Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J., and Avila, J. (2010). GSK3: a possible link between beta amyloid peptide and tau protein. Exp. Neurol. 223, 322-355.
45. Horiuchi, M., Mogi, M., and Iwai, M. (2010). The angiotensin II type 2 receptor in the brain. J. Renin Angiotensin Aldosterone Syst. 11, 1-6.
46. Huang, X., Richards, E., and Sumners, C. (1996a). Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2receptors.J. Biol. Chem. 271, 15635-15641.
47. Huang, X. C., Sumners, C., and Richards, E. M. (1996b). Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. Adv. Exp. Med. Biol. 396, 209-215.
48. Huang, X. C., Richards, E. M., and Sumners, C. (1995). Angiotensin II type 2 receptor-mediated stimulation of protein phosphatase 2A in rat hypothalamic/brainstem neuronal cocultures. J. Neurochem. 65, 2131-2137.
49. Iadecola, C. (2004). Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5, 347-360.
50. Iadecola, C., Park, L., and Capone, C. (2009). Threats to the mind: aging, amyloid, and hypertension. Stroke 40, S40-S44.
51. Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., and Inagami, T. (1995). Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377, 748-750.
52. Iqbal, K., Liu, F., Gong, C. X., Alonso Adel, C., and GrundkeIqbal, I. (2009). Mechanisms of tauinduced neurodegeneration. Acta Neuropathol. 118, 53-69.
53. Iwai, M., Liu, H. W., Chen, R., Ide, A., Okamoto, S., Hata, R., Sakanaka, M., Shiuchi,T.,and Horiuchi,M. (2004). Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110, 843-848.
54. Kang, J., Sumners, C., and Posner, P. (1992). Modulation of net outward current in cultured neurons by angiotensin II: involvement of AT1 and AT2 receptors. Brain Res. 580, 317-324.
55. Kang, J., Sumners, C., and Posner, P. (1993). Angiotensin II type 2 receptor-modulated changes in potassium currents in cultured neurons. Am. J. Physiol. 265, C607-C616.
56. Kaschina, E., Grzesiak, A., Li, J., ForystLudwig, A., Timm, M., Rompe, F., Sommerfeld, M., Kemnitz, U. R., Curato, C., Namsolleck, P., Tschope, C., Hallberg, A., Alterman, M., Hucko, T., Paetsch, I., Dietrich, T., Schnackenburg, B., Graf, K., Dahlof, B., Kintscher, U., Unger, T., and Steckelings, U. M. (2009). Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118, 2523-2532.
57. Kerr, D. S., Bevilaqua, L. R., Bonini, J. S., Rossato, J. I., Kohler, C. A., Medina, J. H., Izquierdo, I., and Cammarota, M. (2005). Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism. Psychopharmacology (Berl.) 179, 529-535.
58. Kilian, P., Campbell, S., Bilodeau, L., Guimond, M., Roberge, C., Gallo-Payet, N., and Payet, M. (2008). Angiotensin II AT2 receptor stimulation increases the rate of NG108-15 cell migration via actin depolymerization. Endocrinology 149, 2923-2933.
59. Klyubin, I., Wang, Q., Reed, M. N., Irving, E. A., Upton, N., Hofmeister, J., Cleary, J. P., Anwyl, R., and Rowan, M. J. (2011). Protection against Abeta-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol. Aging 32, 614-623.
60. LaFerla,F. M.,Green,K. N.,and Oddo,S. (2007). Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8, 499-509.
61. Laflamme, L., Gasparo, M., Gallo, J. M., Payet, M. D., and Gallo-Payet, N. (1996). Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteractedbytheAT1receptors.J. Biol. Chem. 271, 22729-22735.
62. Lenkei, Z., Palkovits, M., Corvol, P., and Llorens-Cortes, C. (1996). Distribution of angiotensin II type-2 receptor (AT2) mRNA expression in the adult rat brain. J. Comp. Neurol. 373, 322-339.
63. Lenkei, Z., Palkovits, M., Corvol, P., and Llorens-Cortes, C. (1997). Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front. Neuroendocrinol. 18:155. doi: 10.1006/frne.1997.0155
64. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G.,Yang,A., Gallagher, M., and Ashe, K. H. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
65. Li, H., Gao, Y., Grobe, J. L., Raizada, M. K., Katovich, M. J., and Sumners, C. (2007a). Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor. Am.J.Physiol. Heart Circ. Physiol. 292, H727- H735.
66. Li, J. M., Mogi, M., Tsukuda, K., Tomochika, H., Iwanami, J., Min, L. J., Nahmias, C., Iwai, M., and Horiuchi, M. (2007b). Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol. Endocrinol. 21, 499-511.
67. Li, J., Culman, J., Hortnagl, H., Zhao, Y., Gerova, N., Timm, M., Blume, A., Zimmermann, M., Seidel, K., Dirnagl, U., and Unger, T. (2005). Angiotensin AT2 receptor protects against cerebral ischemiainduced neuronal injury. FASEB J. 19, 617-619.
68. Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., Trenkwalder, P., and Zanchetti, A. (2003). The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21, 875-886.
69. Liu, R., Gao, M., Qiang, G. F., Zhang, T. T., Lan, X., Ying, J., and Du, G. H. (2009). The anti-amnesic effects of luteolin against amyloid beta(25-35) peptide-induced toxicity in mice involve the protection of neurovascular unit. Neuroscience 162, 1232-1243.
70. Lucius, R., Gallinat, S., Rosenstiel, P., Herdegen, T., Sievers, J., and Unger, T. (1998). The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J. Exp. Med. 188, 661-670.
71. Martineau, D., Lamouche, S., Briand, R., and Yamaguchi, N. (1999). Functional involvement of angiotensin AT2 receptor in adrenal catecholamine secretion in vivo. Can. J. Physiol. Pharmacol. 77, 367-374.
72. Maul, B., von Bohlen Und Halbach, O., Becker, A., Sterner-Kock, A., Voigt, J. P., Siems, W. E., Grecksch, G., and Walther, T. (2008). Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. J. Mol. Med. 86, 563-571.
73. McCarthy, C. A., Vinh, A., Callaway, J. K., and Widdop, R. E. (2009). Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 40, 1482-1489.
74. Meffert, S., Stoll, M., Steckelings, U. M., Bottari, S. P., and Unger, T. (1996). The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 122, 59-67.
75. Mendelsohn, F. A., Allen, A. M., Clevers, J., Denton, D. A., Tarjan, E., and McKinley, M. J. (1988). Localization of angiotensin II receptor binding in rabbit brain by in vitro autoradiography. J. Comp. Neurol. 270, 372-384.
76. Millan, M. A., Jacobowitz, D. M., Aguilera, G., and Catt, K. J. (1991). Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc. Natl. Acad. Sci. U.S.A. 88, 11440-11444.
77. Mogi, M., and Horiuchi, M. (2009). Effects of angiotensin II receptor blockers on dementia. Hypertens. Res. 32, 738-740.
78. Mogi, M., Iwai, M., and Horiuchi, M. (2007a). Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler. Thromb. Vasc. Biol. 27, 2532-2539.
79. Mogi, M., Tsukuda, K., Li, J. M., Iwanami, J., Min, L. J., Sakata, A., Fujita, T., Iwai, M., and Horiuchi, M. (2007b). Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 53, 899-905.
80. Mogi, M., Li, J. M., Iwanami, J., Min, L. J., Tsukuda, K., Iwai, M., and Horiuchi, M. (2006). Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 48, 141-148.
81. Mogi, M., Li, J. M., Tsukuda, K., Iwanami, J., Min, L. J., Sakata, A., Fujita, T., Iwai, M., and Horiuchi, M. (2008). Telmisartan prevented cognitive decline partly due to PPARgamma activation. Biochem. Biophys. Res. Commun. 375, 446-449.
82. Mucke, L. (2009). Neuroscience: Alzheimer's disease. Nature 461, 895-897.
83. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. (2000). High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058.
84. Murugaiah, A. M., Wallinder, C., Mahalingam, A. K., Wu, X., Wan, Y., Plouffe, B., Botros, M., Karlen, A., Hallberg, M., Gallo-Payet, N., and Alterman, M. (2007). Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system. Bioorg. Med. Chem. 15, 7166-7183.
85. Nelson,P. T.,Braak,H.,and Markesbery, W. R. (2009). Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol. 68, 1-14.
86. Nouet, S., Amzallag, N., Li, J. M., Louis, S., Seitz, I., Cui, T. X., Alleaume, A. M., Di Benedetto, M., Boden, C., Masson, M., Strosberg, A. D., Horiuchi, M., Couraud, P. O., and Nahmias, C. (2004). Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J. Biol. Chem. 279, 28989-28997.
87. Okuyama, S., Sakagawa, T., Chaki, S., Imagawa, Y., Ichiki, T., and Inagami, T. (1999). Anxiety-like behavior in mice lacking the angiotensin II type2receptor.Brain Res. 821, 150-159.
88. Phillips, M. I., and de Oliveira, E. M. (2008). Brain renin angiotensin in disease. J. Mol. Med. 86, 715-722.
89. Phillips, M. I., and Sumners, C. (1998). Angiotensin II in central nervous system physiology. Regul. Pept. 78, 1-11.
90. Plouffe, B., Guimond, M. O., Beaudry, H., and Gallo-Payet, N. (2006). Role of tyrosine kinase receptors in angiotensin II AT2 receptor signaling: involvement in neurite outgrowth and in p42/p44mapk activation in NG108-15 cells. Endocrinology 147, 4646-4654.
91. Porrello, E. R., Delbridge, L. M., and Thomas, W. G. (2009). The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front. Biosci. 14, 958-972.
92. Qiu, C., Winblad, B., and Fratiglioni, L. (2005). The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4, 487-499.
93. Reinecke, K., Lucius, R., Reinecke, A., Rickert, U., Herdegen, T., and Unger, T. (2003). Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NFkappaB. FASEB J. 17, 2094-2096.
94. Rodrigues-Ferreira, S., and Nahmias, C. (2010). An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol. Metab. 21, 684-690.
95. Rompe, F., Artuc, M., Hallberg, A., Alterman, M., Stroder, K., Thone Reineke, C., Reichenbach, A., Schacherl, J., Dahlof, B., Bader, M., Alenina, N., Schwaninger, M., Zuberbier, T., Funke-Kaiser, H., Schmidt, C., Schunck, W. H., Unger, T., and Steckelings, U. M. (2010). Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55, 924-931.
96. Rosenstrom, U., Skold, C., Plouffe, B., Beaudry, H., Lindeberg, G., Botros, M., Nyberg, F., Wolf, G., Karlen, A., Gallo-Payet, N., and Hallberg, A. (2005). New selective AT2 receptor ligands encompassing a gammaturn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists. J. Med. Chem. 48, 4009-4024.
97. Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Konig, S., Wittig, B., and Egido, J. (2000). Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ. Res. 86, 1266-1272.
98. Saavedra, J. M., Ando, H., Armando, I., Baiardi, G., Bregonzio, C., Juorio, A., and Macova, M. (2005). Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul. Pept. 128, 227-238.
99. Saavedra, J. M., and Benicky, J. (2007). Brain and peripheral angiotensin II play a major role in stress. Stress 10, 185-193.
100. Sakata, A., Mogi, M., Iwanami, J., Tsukuda, K., Min, L. J., Fujita, T., Iwai, M., Ito, M., and Horiuchi, M. (2009). Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function. Brain Res. 1300, 14-23.
101. Schindowski, K., Belarbi, K., and Buee, L. (2008). Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 7(Suppl. 1), 43-56.
102. Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113.
103. Senbonmatsu, T., Saito, T., Landon, E. J., Watanabe, O., Price, E. Jr., Roberts, R. L., Imboden, H., Fitzgerald, T. G., Gaffney, F. A., and Inagami, T. (2003). A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J. 22, 6471-6482.
104. Shibata, K., Makino, I., Shibaguchi, H., Niwa, M., Katsuragi, T., and Furukawa, T. (1997). Up-regulation of angiotensin type 2 receptor mRNA by angiotensin II in rat cortical cells. Biochem. Biophys. Res. Commun. 239, 633-337.
105. Song, K., Allen, A. M., Paxinos, G., and Mendelsohn, F. A. (1991). Angiotensin II receptor subtypes in rat brain. Clin. Exp. Pharmacol. Physiol. 18, 93-96.
106. Song, K., Allen, A. M., Paxinos, G., and Mendelsohn, F. A. (1992). Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J. Comp. Neurol. 316, 467-484.
107. Srivareerat, M., Tran, T. T., Salim, S., Aleisa, A. M., and Alkadhi, K. A. (2011). Chronic nicotine restores normal Abeta levels and prevents short-term memory and ELTP impairment in Abeta rat model of Alzheimer's disease. Neurobiol. Aging 32, 834-844.
108. Steckelings, U. M., Kaschina, E., and Unger, T. (2005). The AT2 receptor-a matter of love and hate. Peptides 26, 1401-1409.
109. Steckelings, U. M., Rompe, F., Kaschina, E., Namsolleck, P., Grzesiak, A., Funke-Kaiser, H., Bader, M., and Unger, T. (2010a). The past, present and future of angiotensin II type 2 receptor stimulation. J. Renin Angiotensin Aldosterone Syst. 11, 67-73.
110. Steckelings, U. M., Larhed, M., Hallberg, A., Widdop, R. E., Jones, E. S., Wallinder, C., Namsolleck, P., Dahlof, B., and Unger, T. (2010b). Non-peptide AT2-receptor agonists. Curr. Opin. Pharmacol. 11, 1-6.
111. Stegbauer, J., and Coffman, T. M. (2011). New insights into angiotensin receptor actions: from blood pressure to aging. Curr. Opin. Nephrol. Hypertens. 20, 84-88.
112. Tajima, H., Kawasumi, M., Chiba, T., Yamada, M., Yamashita, K., Nawa, M., Kita, Y., Kouyama, K., Aiso, S., Matsuoka, M., Niikura, T., and Nishimoto, I. (2005). A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J. Neurosci. Res. 79, 714-723.
113. Tedesco, M. A., Ratti, G., Mennella, S., Manzo, G., Grieco, M., Rainone, A. C., Iarussi, D., and Iacono, A. (1999). Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am.J.Hypertens. 12, 1130-1134.
114. Tsukuda, K., Mogi, M., Iwanami, J., Min, L. J., Sakata, A., Jing, F., Iwai, M., and Horiuchi, M. (2009). Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptorgamma activation. Hypertension 54, 782-787.
115. Tsukuda, K., Mogi, M., Li, J. M., Iwanami, J., Min, L. J., Sakata, A., Fujita, T., Iwai, M., and Horiuchi, M. (2007). Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 50, 1099-1105.
116. Tsutsumi,K.,and Saavedra,J. M. (1991). Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am. J. Physiol. 261, R209-R216.
117. Unger, T., Badoer, E., Ganten, D., Lang, R. E., and Rettig, R. (1988). Brain angiotensin: pathways and pharmacology. Circulation 77, I40-I54.
118. Unger, T., and Dahlof, B. (2010). Compound 21, the first orally active, selective agonist of the angiotensin II type 2 (AT2) receptor: implications for AT2 receptor research and therapeutic potential. J. Renin Angiotensin Aldosterone Syst. 11, 75-77.
119. Volpe, M., Musumeci, B., De Paolis, P., Savoia, C., and Morganti, A. (2003). Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J. Hypertens. 21, 1429-1443.
120. von Bohlenund Halbach, O., Walther, T., Bader, M., and Albrecht, D. (2001). Genetic deletion of angiotensin AT2 receptor leads to increased cell numbers in different brain structures of mice. Regul. Pept. 99, 209-216.
121. Wan, Y., Wallinder, C., Plouffe, B., Beaudry, H., Mahalingam, A. K., Wu, X., Johansson, B., Holm, M., Botoros, M., Karlen, A., Pettersson, A., Nyberg, F., Fandriks, L., Gallo-Payet, N., Hallberg, A., and Alterman, M. (2004). Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 47, 5995-6008.
122. Wang,J.,Ho,L.,Chen,L.,Zhao,Z.,Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew,S.,Rosendorff,C.,and Pasinetti, G. M. (2007). Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117, 3393-3402.
123. Whitmer, R. A., Gunderson, E. P., Barrett-Connor, E., Quesenberry, C. P. Jr., and Yaffe, K. (2005). Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330, 1360.
124. Widdop, R. E., Jones, E. S., Hannan, R. E., and Gaspari, T. A. (2003). Angiotensin AT2 receptors: cardiovascular hope or hype? Br. J. Pharmacol. 140, 809-924.
125. Wray, S., and Noble, W. (2009). Linking amyloid and tau pathology in Alzheimer's disease: the role of membrane cholesterol in Abetamediated tau toxicity. J. Neurosci. 29, 9665-9667.
126. Wright, J. W., Reichert, J. R., Davis, C. J., and Harding, J. W. (2002). Neural plasticity and the brain renin-angiotensin system. Neurosci. Biobehav. Rev. 26, 529-552.
127. Wruck, C. J., Funke-Kaiser, H., Pufe, T., Kusserow, H., Menk, M., Schefe, J. H.,Kruse,M. L.,Stoll,M.,and Unger, T. (2005). Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler. Thromb. Vasc. Biol. 25, 57-64.
128. Wu, X., Wan, Y., Mahalingam, A. K., Murugaiah, A. M., Plouffe, B., Botros, M., Karlen, A., Hallberg, M., Gallo-Payet, N., and Alterman, M. (2006). Selective angiotensin II AT2 receptor agonists: aryl benzylimidazole structure-activity relationships. J. Med. Chem. 49, 7160-7168.
129. Yaffe, K., Blackwell, T., Kanaya, A. M., Davidowitz, N., Barrett-Connor, E., and Krueger, K. (2004a). Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63, 658-663.
130. Yaffe, K., Kanaya, A., Lindquist, K., Simonsick, E. M., Harris, T., Shorr, R. I., Tylavsky, F. A., and Newman, A. B. (2004b). The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292, 2237-2242.
131. Yamaguchi, Y., and Kawashima, S. (2001). Effects of amyloid-beta(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur. J. Pharmacol. 412, 265-272.
132. Zhou, J., Pavel, J., Macova, M., Yu, Z. X., Imboden, H., Ge, L., Nishioku, T., Dou, J., Delgiacco, E., and Saavedra, J. M. (2006). AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 37, 1271-1276.
133. Zlokovic, B. V. (2005). Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202-208.
134. Zlokovic, B. V. (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.